Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03112174 · ClinicalTrials.gov registry record · Phase 3
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
A Phase 3 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 3
- Development phase
- 366
- Enrollment target
NCT03112174 is a Phase 3 study that has completed, run by Pharmacyclics. The registered enrollment target is 366 participants.
The verdict
NCT03112174, a Phase 3 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 366 participants
- Enrollment target
Study Summary
This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.
Interventions
- DRUG Venetoclax
- DRUG Ibrutinib
- DRUG Placebo Oral tablet to match Venetoclax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2017-06-19 |
| Est. Completion | 2024-06-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03112174
The ClinicalTrials.gov registry entry for NCT03112174 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT03112174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03112174 about?
NCT03112174 is a clinical study titled "Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)". This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.
What is the current status of trial NCT03112174?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 366 participants. The study started on 2017-06-19. Estimated completion is 2024-06-27.
What interventions are being tested in trial NCT03112174?
The interventions under investigation include: Venetoclax (DRUG), Ibrutinib (DRUG), Placebo Oral tablet to match Venetoclax (DRUG).
Who is sponsoring clinical trial NCT03112174?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.